Suppr
超能文献

Minimal residual disease-directed therapy in acute myeloid leukemia.

作者信息

Kayser Sabine, Schlenk Richard F, Grimwade David, Yosuico Victor E D, Walter Roland B

机构信息

Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany;

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;

出版信息

Blood. 2015 Apr 9;125(15):2331-5. doi: 10.1182/blood-2014-11-578815. Epub 2015 Jan 28.

DOI:10.1182/blood-2014-11-578815

PMID:25631772

Abstract

摘要

相似文献

Minimal residual disease-directed therapy in acute myeloid leukemia.

Blood. 2015 Apr 9;125(15):2331-5. doi: 10.1182/blood-2014-11-578815. Epub 2015 Jan 28.

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia.

Blood Cancer J. 2021 Apr 1;11(4):67. doi: 10.1038/s41408-021-00461-z.

Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.

Cancer. 2020 May 15;126(10):2183-2192. doi: 10.1002/cncr.32769. Epub 2020 Feb 26.

Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.

Exp Hematol. 2021 Apr;96:63-72.e3. doi: 10.1016/j.exphem.2021.01.007. Epub 2021 Jan 29.

Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.

Chin J Cancer. 2016 May 19;35:46. doi: 10.1186/s40880-016-0110-6.

The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.

J Hematol Oncol. 2017 Feb 6;10(1):44. doi: 10.1186/s13045-017-0414-2.

Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.

BMC Cancer. 2020 Jun 15;20(1):553. doi: 10.1186/s12885-020-07043-5.

Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.

Int J Hematol. 2008 Sep;88(2):154-158. doi: 10.1007/s12185-008-0108-1. Epub 2008 Jun 17.

Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.

Haematologica. 2015 Mar;100(3):e99-101. doi: 10.3324/haematol.2014.114579. Epub 2014 Dec 5.

Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML.

Blood. 2024 Aug 1;144(5):581-585. doi: 10.1182/blood.2024024264.

引用本文的文献

Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.

Cancer Med. 2024 Feb;13(4):e7074. doi: 10.1002/cam4.7074.

Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group.

Biomedicines. 2022 Jun 28;10(7):1530. doi: 10.3390/biomedicines10071530.

Comparison of the anxiety, depression and their relationship to quality of life among adult acute leukemia patients and their family caregivers: a cross-sectional study in China.

Qual Life Res. 2021 Jul;30(7):1891-1901. doi: 10.1007/s11136-021-02785-6. Epub 2021 Feb 17.

Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia.

Semin Oncol Nurs. 2019 Dec;35(6):150957. doi: 10.1016/j.soncn.2019.150957. Epub 2019 Nov 20.

Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment.

Int J Mol Sci. 2019 Jan 8;20(1):228. doi: 10.3390/ijms20010228.

Minimal/Measurable Residual Disease Monitoring in -Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.

Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492.

Evaluating measurable residual disease in acute myeloid leukemia.

Blood Adv. 2018 Jun 12;2(11):1356-1366. doi: 10.1182/bloodadvances.2018016378.

Universal monitoring of minimal residual disease in acute myeloid leukemia.

JCI Insight. 2018 May 3;3(9):98561. doi: 10.1172/jci.insight.98561.

Targeting minimal residual disease: a path to cure?

Nat Rev Cancer. 2018 Apr;18(4):255-263. doi: 10.1038/nrc.2017.125. Epub 2018 Jan 29.

[How I treat acute myeloid leukemia with t (8;21)].

Zhonghua Xue Ye Xue Za Zhi. 2017 Jan 14;38(1):6-9. doi: 10.3760/cma.j.issn.0253-2727.2017.01.002.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Minimal residual disease-directed therapy in acute myeloid leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译